Stocks · Health care · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA Clue Score36
United States Fiscal year ends December CIK 0001831828 Results filed 5 Nov 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Laurence Matthew Skelton
23 Feb 2026
Chief Commercial Officer
Sell
1,582
$41.98
$66.42K
William D. Turner
23 Feb 2026
Chief Regulatory Officer
Sell
2,187
$41.98
$91.82K
David Lee Johnson
23 Feb 2026
Chief Operating Officer
Sell
2,579
$41.98
$108.28K
Marshall Fordyce
23 Feb 2026
President and CEO
Sell
16,925
$41.98
$710.58K
Sean Grant
23 Feb 2026
Chief Financial Officer
Sell
4,949
$41.98
$207.78K
Joseph R Young
23 Feb 2026
SVP, Finance, Chief Acct Offcr
Sell
3,117
$41.98
$130.86K
Robert Brenner
23 Feb 2026
Chief Medical Officer
Sell
2,151
$41.98
$90.31K
Jason S Carter
21 Nov 2025
Chief Legal Officer
Sell
3,864
$27.82
$107.50K
Joseph R Young
11 Nov 2025
SVP, Finance, Chief Acct Offcr
Sell
15,000
$29.06
$435.87K
Marshall Fordyce
21 Aug 2024
President and CEO
Sell
14,471
$39.76
$575.42K
Joseph R Young
10 Apr 2024
SVP, Finance, Chief Acct Offcr
Sell
5,714
$40.00
$228.56K
Maha Katabi
25 Mar 2024
Director
Sell indirect
340,000
$40.50
$13.77M
Maha Katabi
22 Mar 2024
Director
Sell indirect
413,450
$40.51
$16.75M
Maha Katabi
21 Mar 2024
Director
Sell indirect
13,718
$46.18
$633.50K
Maha Katabi
21 Mar 2024
Director
Sell indirect
12,617
$45.52
$574.33K
Maha Katabi
21 Mar 2024
Director
Sell indirect
21,918
$44.00
$964.39K
Maha Katabi
21 Mar 2024
Director
Sell indirect
32,756
$43.00
$1.41M
Commodore Capital LP
10 Jan 2024
10% owner
Sell indirect
1,050,000
$18.00
$18.90M
Joanne Curley
7 Dec 2022
Chief Development Officer
Sell
494
$16.47
$8.14K
Joanne Curley
9 Nov 2022
Chief Development Officer
Sell
494
$16.54
$8.17K
Joanne Curley
5 Oct 2022
Chief Development Officer
Sell
988
$21.64
$21.38K
Joanne Curley
7 Sep 2022
Chief Development Officer
Sell
988
$18.63
$18.41K
Joanne Curley
3 Aug 2022
Chief Development Officer
Sell
988
$16.81
$16.61K

What was left out

Form 4 filings counted 193
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 7
Sales on a Rule 10b5-1 plan 22
Sales straight out of an exercise 139
Sales at will 23
Transactions with no price 0
Shares from compensation/vesting 16,126,126
Sales filed before the plan box existed 5
History held since 17 May 2021